Track Alpha Tau Medical Ltd. Ordinary Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Alpha Tau Medical Ltd. Ordinary Shares DRTS · Stock Open Alpha Tau Medical Ltd. Ordinary Shares in new tab

13.38 USD
EPS
-1.04
P/B
28.05
ROE
-141.68
Beta
1.29
Target Price
20.60 USD
Loading chart...
Key Metrics
Earnings dateNov. 19, 2026
EPS-1.04
Book Value0.48
Price to Book28.05
Debt/Equity34.39
% Insiders31.367%
Estimates
Forward P/E-24.84
Forward EPS-0.54
Target Mean Price20.60

DCF valuation

Model fair value for Alpha Tau Medical Ltd. Ordinary Shares (DRTS)
Result
Sign in to run the valuation for DRTS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus Strong buy · mean target 20.60 USD (low 16.00, high 30.00) · as of 15 Nov 2026
Low 16.00
Mean 20.60
High 30.00
Price 13.38
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Alpha Tau Medical Ltd. Ordinary Shares Logo Alpha Tau Medical Ltd. Ordinary Shares Analysis (DRTS)

Israel Health Care Official Website Stock

Is Alpha Tau Medical Ltd. Ordinary Shares a good investment? Alpha Tau Medical Ltd. Ordinary Shares (DRTS) is currently trading at 13.38 USD. Market analysts have a consensus price target of 20.60 USD. This suggests a potential upside from current levels.

Earnings Schedule: Alpha Tau Medical Ltd. Ordinary Shares is expected to release its next earnings report on Nov. 19, 2026. The market consensus estimate for Forward EPS is -0.54.

Investor FAQ

Does Alpha Tau Medical Ltd. Ordinary Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is Alpha Tau Medical Ltd. Ordinary Shares?

Alpha Tau Medical Ltd. Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 19, 2026. The company currently has a trailing EPS of -1.04.

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.

Exchange Ticker
NMS (United States) DRTS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion